Stay updated on Autogene Cevumeran Combo With Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Autogene Cevumeran Combo With Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the Autogene Cevumeran Combo With Pembrolizumab in Melanoma Clinical Trial page
- Check5 days agoChange DetectedAdded: Revision v3.5.2; Deleted: Revision v3.5.0.SummaryDifference0.0%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check34 days agoChange DetectedRevision label updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check41 days agoChange Detected- The page shows a revision label updated from v3.4.2 to v3.4.3, a minor site metadata update that does not alter study content or functionality.SummaryDifference0.0%

- Check70 days agoChange DetectedRevision: v3.4.2 has been added. The notices about government funding and the prior Revision: v3.4.1 have been removed.SummaryDifference0.3%

- Check77 days agoChange DetectedResults were posted and key endpoints (PFS, ORR, OS, DOR) and health-related QoL data were added, with RECIST criteria and cross-over details described.SummaryDifference2%

- Check84 days agoChange DetectedAdded a Show glossary option; updated the label 'Last Update Submitted that Met QC Criteria' with new capitalization and bumped the revision to v3.4.0, while removing the older 'Last Update Submitted that met QC Criteria' and 'No FEAR Act data' labels.SummaryDifference0.2%

Stay in the know with updates to Autogene Cevumeran Combo With Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Autogene Cevumeran Combo With Pembrolizumab in Melanoma Clinical Trial page.